NANOBIOTIX Appoints Renowned Global Experts to Comprehensive Scientific Advisory Board for Potential First-in-Class Radioenhancer NBTXR3
“Bringing a disruptive, potentially first-in-class therapeutic to patients around the world requires a deep, multidisciplinary understanding of the complex clinical research landscape along with the requirements of cutting-edge patient care in the real world,” said Leonard Farber, MD, Chief Clinical and Medical Affairs Officer at Nanobiotix and Chairman of the Scientific Advisory Board.
NDA for New Second-Line Indication of CAR T-Cell Therapy Product YIKAIDA (Axicabtagene Ciloleucel Injection) Approved for CDE Review
"The NDA for new second-line indication of YIKAIDA was recently approved by the CDE of NMPA for review, which inspired the staff at Fosun Kite." Huang Hai, CEO of Fosun Kite, said, "As a high-tech biomedical enterprise, we will strive to benefit more patients through our practical pioneering and innovation."
Astrea Bioseparations Introduces Nereus LentiHERO, a Fit-for-purpose Solution for Lentiviral Vector Purification
“We believe that AstreAdept will be a game-changer,” explained Astrea Bioseparations’ CEO Terry Pizzie. “Our approach was to rapidly develop and incorporate this material into the Nereus LentiHERO, a simple, fit-for-purpose device that radically transforms how lentivirus can be purified [in terms of speed, recovery, and efficiency].
“IEEE publishes many peer-reviewed journals that cover the intersection of engineering and other domains including biotechnology, telecommunications, power and energy. Publications related to the life sciences include IEEE Transactions on Computational Biology and Bioinformatics, IEEE Journal of Biomedical and Health Informatics, and IEEE Reviews in Biomedical Engineering. We believe access to this information for our Foundation customers will be of tremendous value,” said Steve Goldstein, CEO of ResoluteAI.
CEO Yvonne Lungershausen said Avance Clinical is now the leading Australian-based biotech CRO with US operations.